Literature DB >> 15332331

High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications.

F Giammarile1, L E Cinotti, A Jouvet, J M Ramackers, G Saint Pierre, P Thiesse, E Jouanneau, J Guyotat, I Pelissou-Guyotat, A Setiey, J Honnorat, D Le Bars, D Frappaz.   

Abstract

Classification and treatment strategy of oligodendrogliomas (ODG) remain controversial. Imaging relies essentially on contrast enhancement using CT or MRI. The aim of our study was to use positron emission tomography (PET) using [18F]-flurodeoxyglucose (FDG) and [11C]-L-methyl-methionine (MET) to evaluate metabolic characteristics of ODG. We studied 19 patients with proven ODG, comparing standardized uptake values (SUV) and maximal tumor/contralateral normal tissues ratios (T/N). Imaging findings were compared with WHO, Smith and Daumas-Duport classifications. Uptake of FDG was decreased only in 8 patients, independently of grading, while MET uptake was always increased. MET uptake was significantly higher for high grade tumors grouped according to Smith or Daumas-Duport classifications, while no significant difference in MET uptake was found when using WHO classification. A different correlation was found between FDG and MET uptakes in normal tissues and high grade tumors. A trend for improved progression free survival was found for tumors that lacked contrast enhancement on MRI or those showing low FDG or MET uptake. In conclusion, MET appeared more sensitive than FDG to detect proliferation in ODG. The preferential protein metabolism, already noticeable for low-grade tumor, correlated with glucose metabolism and helped to separate, in vivo, high and low grade tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332331     DOI: 10.1023/b:neon.0000033384.43417.82

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Oligoastrocytomas: a clinicopathological study of 52 cases.

Authors:  H G Krouwer; S G van Duinen; W Kamphorst; P van der Valk; A Algra
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

5.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

6.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

7.  Primary intraventricular oligodendrogliomas.

Authors:  T M Markwalder; P Huber; R V Markwalder; R W Seiler
Journal:  Surg Neurol       Date:  1979-01

8.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.

Authors:  G Reifenberger; J Reifenberger; K Ichimura; P S Meltzer; V P Collins
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

9.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

10.  Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography.

Authors:  A Lilja; K Bergström; P Hartvig; B Spännare; C Halldin; H Lundqvist; B Långstrom
Journal:  AJNR Am J Neuroradiol       Date:  1985 Jul-Aug       Impact factor: 3.825

View more
  14 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

Review 2.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

3.  Increased L-[1-11 C] leucine uptake in the leptomeningeal angioma of sturge-weber syndrome: a PET study.

Authors:  Bálint Alkonyi; Harry T Chugani; Otto Muzik; Diane C Chugani; Senthil K Sundaram; William J Kupsky; Carlos E Batista; Csaba Juhász
Journal:  J Neuroimaging       Date:  2011-01-11       Impact factor: 2.486

4.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

5.  Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.

Authors:  Abderrahmane Hamlat; Stephan Saikali; Jacques Chaperon; Beatrice Carsin-Nicol; Michéle Le Calve; Thierry Lesimple; Mohamed Ben-hassel; Yvon Guegan
Journal:  J Neurooncol       Date:  2006-09       Impact factor: 4.130

Review 6.  Low-grade gliomas: the debate continues.

Authors:  Paul D Brown
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

7.  Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases.

Authors:  Shigeru Yamaguchi; Hiroyuki Kobayashi; Kenji Hirata; Tohru Shiga; Shinya Tanaka; Junichi Murata; Shunsuke Terasaka
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

8.  Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Authors:  T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

9.  [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

10.  Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.

Authors:  Takeko Nojiri; Tadashi Nariai; Masaru Aoyagi; Michio Senda; Kenji Ishii; Kiichi Ishiwata; Kikuo Ohno
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.